Is Psilocybin Legal in Canada?

⚠️ Not Legal Advice

This page is for educational purposes only and does not constitute legal advice. Drug laws change frequently and vary by region within a country. Always verify the current status with Health Canada's Controlled Substances and Precursor Chemicals page (https://www.canada.ca/en/health-canada/services/controlled-substances-precursor-chemicals.html) or a qualified local lawyer before making any decisions. A Section 56 exemption is granted to a named individual for a specific, approved purpose — it is not transferable and does not make psilocybin generally legal in Canada. Do not assume that because exemptions exist, general possession or sale is tolerated.

Last reviewed: July 2026. This entry is drawn from Psilobase's broader Legal Status by Country guide. Because psilocybin law is an actively moving target worldwide, treat any date-stamped legal claim — including this one — as needing re-verification if you are reading it more than a few months after the review date above.

Quick Answer

No, psilocybin remains illegal for general use in Canada — it is a Schedule III substance under the Controlled Drugs and Substances Act (CDSA). However, since 2020 Health Canada has granted a growing number of individual Section 56 exemptions allowing terminally ill patients, licensed therapists in training, and some healthcare providers to legally access or administer psilocybin outside a clinical trial.

Current Legal Status in Canada

Unauthorized possession of psilocybin can result in up to 3 years' imprisonment; trafficking or production carries penalties of up to 10 years. These penalties apply to anyone without a valid Section 56 exemption or clinical trial authorization. The exemption process is individual and case-by-case — it is not a general legalization and does not create a right to possess or use psilocybin outside the specific approved context (e.g., a specific patient's end-of-life care, or a specific practitioner's approved training session). Simply having a terminal diagnosis does not automatically grant an exemption; a formal application supported by a healthcare provider is required, and processing can take months.

History: How the Law Got Here

Psilocybin has been controlled under Canadian federal law for decades, listed as a Schedule III substance under the CDSA. The turning point came in August 2020, when Health Canada granted Section 56 exemptions to four terminally ill Canadians seeking psilocybin-assisted therapy for end-of-life distress — the first such exemptions in the country's history. Since then, the advocacy organization TheraPsil has helped over 100 individuals, including patients and healthcare practitioners seeking training, obtain similar exemptions. Clinical trials involving psilocybin have also expanded across Canadian universities and hospitals. As of 2026, no legislation has been passed to broaden access beyond this individual-exemption model, though reform proposals have been discussed in Parliament.

How to Verify This Yourself

Laws referenced on this page were last reviewed in July 2026. Before making any decision based on legal status, check directly with Health Canada's Controlled Substances and Precursor Chemicals page: https://www.canada.ca/en/health-canada/services/controlled-substances-precursor-chemicals.html. For broader cross-country comparison and additional official sources (DEA, Home Office, Health Canada, TGA, EMCDDA, etc.), see the full Legal Status by Country guide.